William G.  Rice net worth and biography

William Rice Biography and Net Worth

Through a rich blend of leadership roles in industry, government, and academic sectors, Dr. William Rice has accrued more than 25 years of know-how and forged a diverse set of skills, including executive, operational, business development, financial, product research, and development. Before Aptose, Dr. Rice served as the president, chief executive officer and chairman of the board of Cylene Pharmaceuticals, Inc. In that role he led the company’s strategic, financing, and business development activities, resulting in the development and sale of small molecule therapeutic programs designed to exploit CK2-mediated pathways and non-genotoxic mechanisms for activating p53 to kill cancer cells. Before Cylene, Dr. Rice was the founder, president, chief executive officer, and director of Achillion Pharmaceuticals, Inc. He also served as a senior scientist and head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine. Throughout his career, Dr. Rice has identified multiple new molecular drug targets, delivered multiple first-in-class drugs to the clinic, and published peer-reviewed findings in Science, Nature, Cancer Cell, Nature Medicine, Proceedings of the National Academy of Sciences, among other prestigious journals. Dr. Rice holds a Doctor of Philosophy in Biochemistry from Emory University and was a postdoctoral trainee in the Department of Internal Medicine at the University of Michigan Medical Center.

What is William G. Rice's net worth?

The estimated net worth of William G. Rice is at least $171,097.31 as of November 25th, 2024. Dr. Rice owns 613,252 shares of Aptose Biosciences stock worth more than $171,097 as of December 22nd. This net worth estimate does not reflect any other assets that Dr. Rice may own. Learn More about William G. Rice's net worth.

How old is William G. Rice?

Dr. Rice is currently 59 years old. There are 2 older executives and no younger executives at Aptose Biosciences. Learn More on William G. Rice's age.

How do I contact William G. Rice?

The corporate mailing address for Dr. Rice and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]. Learn More on William G. Rice's contact information.

Has William G. Rice been buying or selling shares of Aptose Biosciences?

In the last ninety days, William G. Rice has bought $20,000.00 in shares of Aptose Biosciences stock. Most recently, on Monday, November 25th, William G. Rice bought 100,000 shares of Aptose Biosciences stock. The stock was acquired at an average cost of $0.20 per share, with a total value of $20,000.00. Following the completion of the transaction, the chief executive officer now directly owns 613,252 shares of the company's stock, valued at $122,650.40. Learn More on William G. Rice's trading history.

Who are Aptose Biosciences' active insiders?

Aptose Biosciences' insider roster includes Rafael Bejar (VP), Denis Burger (Director), Erich Platzer (Director), William Rice (CEO), Warren Whitehead (Director), and Donald Wilson, Jr. (Major Shareholder). Learn More on Aptose Biosciences' active insiders.

Are insiders buying or selling shares of Aptose Biosciences?

In the last twelve months, Aptose Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $20,000.00. The most recent insider tranaction occured on November, 25th when CEO William G Rice bought 100,000 shares worth more than $20,000.00. Insiders at Aptose Biosciences own 3.9% of the company. Learn More about insider trades at Aptose Biosciences.

Information on this page was last updated on 11/25/2024.

William G. Rice Insider Trading History at Aptose Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/25/2024Buy100,000$0.20$20,000.00613,252View SEC Filing Icon  
9/19/2022Buy666$10.20$6,793.2024,216View SEC Filing Icon  
6/6/2022Buy666$14.55$9,690.3023,550View SEC Filing Icon  
12/15/2021Buy1,188$16.80$19,958.40View SEC Filing Icon  
11/26/2021Buy576$34.65$19,958.40View SEC Filing Icon  
7/2/2021Buy405$49.35$19,986.75View SEC Filing Icon  
7/10/2020Sell11,259$90.75$1,021,754.2519,834View SEC Filing Icon  
3/25/2020Buy226$87.30$19,729.8031,094View SEC Filing Icon  
10/24/2019Buy666$28.80$19,180.8010,867View SEC Filing Icon  
4/18/2019Buy666$27.75$18,481.5010,200View SEC Filing Icon  
3/14/2019Buy666$28.50$18,981.009,534View SEC Filing Icon  
See Full Table

William G. Rice Buying and Selling Activity at Aptose Biosciences

This chart shows William G Rice's buying and selling at Aptose Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aptose Biosciences Company Overview

Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $0.28
Low: $0.21
High: $0.39

50 Day Range

MA: $0.30
Low: $0.17
High: $0.40

2 Week Range

Now: $0.28
Low: $0.13
High: $2.68

Volume

304,802,594 shs

Average Volume

1,745,122 shs

Market Capitalization

$16.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06